Jeff Bezos, the founder and former CEO of Amazon, has reportedly made an investment in an up-and-coming anti-aging biotech company called Altos Labs, MIT Tech Review reports. Founded earlier this year, Altos Labs is focused on finding ways to reverse the aging process and develop an innovative technology to reprogram human cells.
According to the report, Jeff Bezos is among the pool of investors who have funded the biotech company’s research initiatives to find viable ways to reverse the aging process in humans. The biotech startup is supposedly also seeking to hire more scientists for its ongoing project, offering annual salaries of up to USD 1 million.
However, it is worth noting that Bezos Expeditions, Bezos’ investment office, has not disclosed any details about the investment as of yet.
Sources cite, Altos Labs would largely be focusing on a technology dubbed ‘reprogramming’. Reprogramming apparently involves the introduction of proteins to a cell, which essentially instruct the cell to revert to a stem-cell-like condition.
Scientist Shinya Yamanaka, who had won a joint Nobel Prize back in 2012 for demonstrating the procedure in mice, would join as chair of Alto Labs' scientific advisory council. Yamanaka believes that, despite multiple obstacles, there is immense potential in the field.
According to Delaware’s state records, Altos Labs was first incorporated back in April 2021, while records from UK Companies House, the UK’s registrar of companies, show that the firm was incorporated in the nation back in June. Reportedly, Altos Labs intends to set up institutes in the UK, California, and Japan.
For the uninitiated, Amazon founder Jeff Bezos resigned from the position of CEO of the multinational conglomerate in July 2021. In a February letter addressed to Amazon employees, Bezos stated that he would devote his attention to philanthropic endeavors and passion projects, such as his space exploration project, Blue Origin.
Bezos has seemingly invested in an anti-aging research initiative before, back in 2018, when he injected capital in biotech company, Unity Technologies, which focuses on developing anti-aging therapies.